was well tolerated in the study with a low incidence of adverse events and no treatment-related serious adverse events. The most frequently reported treatment-related adverse events (>2% and greater than placebo) were dry mouth and application-site reactions (5.4%).
Additional pharmacology studies showed that showering one hour or later, or applying sunscreen lotion 30 minutes before or after GELNIQUE application, did not significantly alter the absorption of the drug.
For full prescribing information, please visit www.gelnique.com.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., (NYSE: WPI) is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical).
In the U.S., the Watson portfolio includes RAPAFLO, GELNIQUE, TRELSTAR(R) LA and TRELSTAR(R) Depot, Ferrlecit(R), INFeD(R) and Oxytrol(R). In addition, Watson markets the following brands under co-promotion agreements: AndroGel(R), with Solvay Pharmaceuticals, Inc., and Femring(R), with Warner Chilcott Limited. The Watson pipeline portfolio includes a number of products, including a six-month formulation of TRELSTAR(R), for the treatment of advanced prostate cancer which is currently under review by the FDA; URACYST(R), under development for cystitis; and a novel new oral contraceptive.
For press releases and other company information, visit the Watson website at http://www.watson.com.
Any statements contained in
Page: 1 2 3 4 Related medicine news :1
|SOURCE Watson Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Watson-Marlow Releases Informative Video Featuring Showcased High Purity Pumps, Tubing and Fillers at Interphex 2009 2
. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook3
. Watson Files FDA Applications for Generic Mucinex(R)4
. Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting5
. Companies Continue To Add Wellness Programs, Watson Wyatt/National Business Group On Health Survey Finds6
. Mark G. Watson Named Executive Director of Radiological Society of North America7
. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium8
. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook9
. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement10
. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation11
. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum